BIOGEN IDEC Inc. (NQ: BIIB)
290.54 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(BIIB) Community Analysis from
April 20, 2014
(Jutia Group, 4/14/14)
[Business Wire] - Biogen Idec will present more than 60 company-sponsored platform and poster...(read more)
(Stock Blog Hub, 3/30/13)
Tecfidera, Biogen Idec’s (BIIB) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms...(read more)
(Wealth Daily, 2/8/13)
Biotech company Biogen Idec (NASDAQ: BIIB) will purchase the rights to the multiple sclerosis drug developed by its partner...
Biogen Idec (BIIB) Company Overview

Biogen Idec (NASDAQ:BIIB) is a biotechnology company that makes drugs to treat cancer, neurological diseases, and autoimmune diseases. The company's most important products are Avonex and Rituxan, which treat multiple sclerosis (MS) and non-Hodgkin's lymphomas (NHLs), respectively. The company earned $4.4 billion in revenue and $970 million in net income in 2009.[1]

Biogen has high hopes for Tysabri, a new multiple sclerosis drug that has the potential to become a major blockbuster. However, Tysabri was withdrawn from the market in 2005 after it was linked to a rare brain disease. After two years of safety reviews, the FDA has reapproved the drug which is currently being relaunched. However, investors still consider Tysabri a significant risk and a make-or-break issue for the company.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here